Cargando…
The impact of the COVID‐19 pandemic on melanoma diagnoses
INTRODUCTION: We investigated whether governmental measures and lockdowns during the COVID‐19 pandemic had an impact on the number and histopathologic stages of melanoma. METHODS: The number and thickness (Breslow) of all diagnosed melanomas per day, month, or period at the ‘Institute for Pathology...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088572/ https://www.ncbi.nlm.nih.gov/pubmed/37829553 http://dx.doi.org/10.1002/jvc2.15 |
_version_ | 1784704355097640960 |
---|---|
author | Weltler, Patrick Rappersberger, Klemens Filzmoser, Peter Vujic, Igor |
author_facet | Weltler, Patrick Rappersberger, Klemens Filzmoser, Peter Vujic, Igor |
author_sort | Weltler, Patrick |
collection | PubMed |
description | INTRODUCTION: We investigated whether governmental measures and lockdowns during the COVID‐19 pandemic had an impact on the number and histopathologic stages of melanoma. METHODS: The number and thickness (Breslow) of all diagnosed melanomas per day, month, or period at the ‘Institute for Pathology in the Centre’ in 2019 and 2020 were compared. For 2020, we defined four time periods: Period 1: 1 January–15 March; Period 2: 16 March–15 May (Lockdown 1); Period 3: 16 May–2 November; Period 4: 3 November–7 December (Lockdown 2). RESULTS: We found similar melanoma numbers in 2019 (577) and 2020 (608). The mean number of diagnoses per day during Lockdown 1 (Period 2) was significantly lower (0.87 melanomas/day; p = 0.005) when compared to the respective time periods in 2019 and to the other three periods in 2020 (Period 1: 1.65 melanomas/day, Period 3: 1.77 melanomas/day, and Period 4: 2.49 melanomas/day). Tumour thickness in July 2020 (1.9 mm) was significantly higher (p = 0.02) than in July 2019 (1.1 mm). DISCUSSION: The significant lower number of histopathologic diagnoses of melanoma during ‘Lockdown 1’ may be explained by postponed or missed patient consultations. This assumption is supported by the demonstration of a higher tumour thickness in July and August 2020, compared to 2019. |
format | Online Article Text |
id | pubmed-9088572 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90885722022-05-10 The impact of the COVID‐19 pandemic on melanoma diagnoses Weltler, Patrick Rappersberger, Klemens Filzmoser, Peter Vujic, Igor JEADV Clinical Practice Short Reports INTRODUCTION: We investigated whether governmental measures and lockdowns during the COVID‐19 pandemic had an impact on the number and histopathologic stages of melanoma. METHODS: The number and thickness (Breslow) of all diagnosed melanomas per day, month, or period at the ‘Institute for Pathology in the Centre’ in 2019 and 2020 were compared. For 2020, we defined four time periods: Period 1: 1 January–15 March; Period 2: 16 March–15 May (Lockdown 1); Period 3: 16 May–2 November; Period 4: 3 November–7 December (Lockdown 2). RESULTS: We found similar melanoma numbers in 2019 (577) and 2020 (608). The mean number of diagnoses per day during Lockdown 1 (Period 2) was significantly lower (0.87 melanomas/day; p = 0.005) when compared to the respective time periods in 2019 and to the other three periods in 2020 (Period 1: 1.65 melanomas/day, Period 3: 1.77 melanomas/day, and Period 4: 2.49 melanomas/day). Tumour thickness in July 2020 (1.9 mm) was significantly higher (p = 0.02) than in July 2019 (1.1 mm). DISCUSSION: The significant lower number of histopathologic diagnoses of melanoma during ‘Lockdown 1’ may be explained by postponed or missed patient consultations. This assumption is supported by the demonstration of a higher tumour thickness in July and August 2020, compared to 2019. John Wiley and Sons Inc. 2022-03-13 2022-06 /pmc/articles/PMC9088572/ /pubmed/37829553 http://dx.doi.org/10.1002/jvc2.15 Text en © 2022 The Authors. JEADV Clinical Practice published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Reports Weltler, Patrick Rappersberger, Klemens Filzmoser, Peter Vujic, Igor The impact of the COVID‐19 pandemic on melanoma diagnoses |
title | The impact of the COVID‐19 pandemic on melanoma diagnoses |
title_full | The impact of the COVID‐19 pandemic on melanoma diagnoses |
title_fullStr | The impact of the COVID‐19 pandemic on melanoma diagnoses |
title_full_unstemmed | The impact of the COVID‐19 pandemic on melanoma diagnoses |
title_short | The impact of the COVID‐19 pandemic on melanoma diagnoses |
title_sort | impact of the covid‐19 pandemic on melanoma diagnoses |
topic | Short Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088572/ https://www.ncbi.nlm.nih.gov/pubmed/37829553 http://dx.doi.org/10.1002/jvc2.15 |
work_keys_str_mv | AT weltlerpatrick theimpactofthecovid19pandemiconmelanomadiagnoses AT rappersbergerklemens theimpactofthecovid19pandemiconmelanomadiagnoses AT filzmoserpeter theimpactofthecovid19pandemiconmelanomadiagnoses AT vujicigor theimpactofthecovid19pandemiconmelanomadiagnoses AT weltlerpatrick impactofthecovid19pandemiconmelanomadiagnoses AT rappersbergerklemens impactofthecovid19pandemiconmelanomadiagnoses AT filzmoserpeter impactofthecovid19pandemiconmelanomadiagnoses AT vujicigor impactofthecovid19pandemiconmelanomadiagnoses |